TrialMedicine2016

Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma.

Cheng-Jeng Tai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.